APG Asset Management US Inc. Decreases Holdings in IQVIA Holdings Inc. (NYSE:IQV)

APG Asset Management US Inc. trimmed its stake in IQVIA Holdings Inc. (NYSE:IQV) by 51.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,767 shares of the medical research company’s stock after selling 3,981 shares during the period. APG Asset Management US Inc.’s holdings in IQVIA were worth $740,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of IQV. Synergy Asset Management LLC purchased a new stake in IQVIA in the 4th quarter worth $33,000. Lee Danner & Bass Inc. bought a new position in shares of IQVIA in the 4th quarter valued at about $44,000. Zions Bancorporation N.A. lifted its holdings in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 85 shares during the last quarter. Versant Capital Management Inc lifted its holdings in shares of IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in IQVIA in the 4th quarter worth about $60,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Trading Up 8.7 %

IQV opened at $157.02 on Thursday. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88. The stock has a market capitalization of $27.68 billion, a PE ratio of 20.94, a P/E/G ratio of 1.99 and a beta of 1.46. The business’s 50 day moving average price is $184.54 and its 200 day moving average price is $200.91. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analyst Weigh In

IQV has been the topic of a number of research reports. Stephens began coverage on shares of IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 target price on the stock. Robert W. Baird lowered their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, January 21st. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Bank of America lowered their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Five investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $247.10.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.